Psychiatric Symptoms in a Patient with Influenza A (H1N1) Treated with Oseltamivir (Tamiflu): A Case Report
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Oseltamivir is the most common antiviral drug used to treat and prevent influenza. Epidemiological studies performed in Japan, the United States, and the United Kingdom indicate that oseltamivir may cause psychiatric symptoms; however, the underlying mechanism has not been elucidated. In South Korea, interest in oseltamivir has increased with the spread of the new influenza virus; however, no case report or investigation of psychiatric symptoms associated with the drug has been reported to date. Here, we report a case of a 22-year-old male who complained of mood swings, suicidal feelings, auditory hallucinations, memory deterioration, and insomnia after taking oseltamivir.
Abstract
Oseltamivir is the most common antiviral drug used to treat and prevent influenza. Epidemiological studies performed in Japan, the United States, and the United Kingdom indicate that oseltamivir may cause psychiatric symptoms; however, the underlying mechanism has not been elucidated. In South Korea, interest in oseltamivir has increased with the spread of the new influenza virus; however, no case report or investigation of psychiatric symptoms associated with the drug has been reported to date. Here, we report a case of a 22-year-old male who complained of mood swings, suicidal feelings, auditory hallucinations, memory deterioration, and insomnia after taking oseltamivir.
참고문헌 (12)
- National Institute for Clinical Excellence., "Guidance on the use of zanamivir, olsetamivir and amantadine for the treatment of influenza: Technology appraisal guidance. 4th ed" (2010), National Institute for Clinical Excellence
- Turner D., "Systematic review and economic decision modeling for the prevention and treatment of influenza A and B", Health Technol Assess, 7, pp.iii-iv~xi-xiii (2003)
- Toovey S., "Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir : a comprehensive review", Drug Saf, 31, pp.1097~1114 (2008)
- Maxwell SR., "Tamiflu and neuropsychiatric disturbance in adolescents", BMJ, 334, pp.1232~1233 (2007)
- Fuyuno I., "Tamiflu side effects come under scrutiny", Nature, 446, pp.358~359 (2007)
- Safety alerts for drugs, biologist, medical devices, and dietary supplements. The FDA safety information and adverse event reporting program. 12th ed, "US Food and Drug Administration.", US Food and Drug Administration, ~ (2011)
- US Ministry of Health., "Working group for clinical investigation for oseltamivir phosphate. 1st ed" (2007), US Ministry of Health
- Matheson NJ., "Neuraminidase inhibitors for preventing and treating influenza in children", Cochrane Database Syst Rev, (1), pp.CD002744~ (2007)
- Izumi Y., "Neuroexcitatory actions of Tamiflu and its carboxylate metabolite", Neurosci Let, 426, pp.54~58 (2007)
- Satoh K., "Effects of oseltamivir phosphate(Tamiflu)and its metabolite(GS4071)on monoamine neurotransmission in the rat brain", Biol Pharm Bull, 30, pp.1816~1818 (2007)
- Ose A., "P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier", Drug Metab Dispos, 36, pp.427~434 (2008)
- Hama R., "Fatal neuropsychiatric adverse reactions to oseltamivir : Case series and overview of casual relationships", Int J Risk Saf Med, 20, pp.5~36 (2008)